Medicine

MIT researchers have invented a digestible, bioresorbable battery that can deliver drugs directly to the GI tract, reports Smithsonian Magazine’s Sara Hashemi. Prof. Giovanni Traverso and his colleagues “made two versions of the battery of different sizes and voltages,” writes Hashemi. “Exposing them to an acidic liquid similar to gastric fluid revealed they would function normally in the stomach for about three days.” 

The Economist highlights MIT researchers’ new “paper-based battery whose components are safely absorbed by the body,” to help deliver drugs to the GI tract more effectively. “The new battery is a stack of magnesium, gel and chemically active paper—all coated in wax to protect it from the harsh environment of the gut. It is also compact, taking up only about a quarter of the space inside a standard gelatine capsule, leaving plenty of room for the device it is to power, as well as other useful payloads, such as a drug.”  

MIT researchers have developed an ingestible battery that could be used to monitor drug delivery and avoid the need for surgery; a “milestone towards potential human use for health monitoring and treatments,” writes Michael Peel for the Financial Times. Improving the effectiveness of therapies “moves the technology beyond a materials demonstration toward an integrated biomedical system,” says Prof. Giovanni Traverso, senior author of the study.  

The Financial Times’ Anjana Ahuja highlights Prof. Sangeeta Bhatia and Senior Postdoctoral Associate Vardhman Kumar’s work developing injectable “mini livers,” tissue grafts that could “take on some of the life-saving functions of liver cells: helping with blood clotting, detoxifying the bloodstream and breaking down medicines. The injectable grafts, they suggest, could also be used as a bridging treatment while patients wait for a transplant, with booster injections able to dial up the dose,” writes Ahuja.  

Prof. Jonathan Weissman speaks with The New York Times’ Emily Baumgaertner Nunn about epigenome editing, including a single injection that would silence a gene in the liver that destroys receptors responsible for clearing LDL cholesterol. “This is sort of the ultimate one-and-done treatment,” says Weissman. “I don’t think we know enough to be able to do it at the moment, but it is not so far off from what’s imaginable.”  

In a STAT opinion piece, Arya Rao, a candidate in the Harvard/MIT MD-PhD program, and Marc Succi write about how AI impacts clinical reasoning. “[C]linical reasoning and model reasoning are not the same thing,” Rao and Succi explain. “AI not only lacks this hidden framework and data repository for learning, but it arrives at conclusions using a fundamentally different method.” 

Jay Fox of the Ohio News Network joins Ohio 10 WBNS to discuss his conversation with President Sally Kornbluth about how life-changing scientific innovations in university research labs have helped build our nation’s technological prowess and ensured our strength and stability, explaining how federal research cuts threaten future medical and technological advances. “What’s at risk are the kind of cures and technological advances that we’ll enjoy as we age, as our children get older and their children’s children get older. It’s really the future that is being mortgaged at this point,” said Kornbluth during her discussion with Fox. 

Popular Science reporter Laura Baisas showcases an ingestible, berry-size thermometer developed by MIT researchers that could offer continuous monitoring for sick patients. The sensor “could make it easier to determine whether a patient is sick and if they’re at risk of developing a dangerously high fever. It can also help for people tracking their fertility or those under anesthesia," writes Baisas. "The team is now working on combining the temperature sensor with different sensors that could measure other vital signs such as heart rate." 

Inside Precision Medicine spotlights Prof. Giovanni Traverso and his team’s work developing an oral drug formulation containing hydrogel that allows for the delivery of small molecules and antibodies via the esophageal mucosal lining. “We were interested in delivering anti-TNFs as a model drug, but also to help people who suffer from conditions like Crohn’s disease to have options that could be delivered to the site,” says Traverso. “If we have the possibility of site-directed delivery, we may be able to mitigate systemic side effects from these immunosuppressing agents.”

In a Forbes article, contributor Wes Kilgore cites a study by MIT economists that reveals how timely hospice use can create healthcare savings in the U.S. “When families avoid hospice because of fear or legal confusion, patients return to emergency rooms, see specialists, undergo procedures, and drive-up Medicare costs,” writes Kilgore. 

Moving Health, a D-Lab spinout founded by MIT students, tackles maternal mortality in rural Ghana by decreasing transport time to hospitals. CNN reporter Maya Baylis highlights how Moving Health’s tricycle ambulances were designed to navigate narrow, rough roads in areas where ambulances are scarce or impractical. “Sometimes the biggest barrier to surviving a medical emergency isn’t the lack of hospitals,” says Emily Young ‘18, CEO and co-founder of Moving Health, “it’s being able to get there in time.”

Nature reporter Jyoti Madhusoodanan features Prof. Regina Barzilay and Prof. James Collin’s work developing AI tools aimed at accelerating the process of drug discovery and tackling the growing problem of antibiotic resistance. Barzilay notes that the goal of AI-based drug design is not to have the perfect method, but to find working solutions to the antibiotic-resistance crisis. “To me, the art is really in taking the tools we currently have, which are already doing quite a bit, and translating them into something which is useful in clinic,” she explains. 

The Economist reports on the growing popularity of ingestible sensors, including work at MIT where researchers are using the devices to “sense internal conditions and act on what they find.”  The MIT team “received $66m from ARPA-H, a federal grant system that pushes high-risk, transformative health-care technology, to develop ingestible devices for the oral delivery of mRNA treatments.” 

Senior Research Scientist Leo Celi joins GBH News' Curiosity Desk for a panel discussion on how the information given to AI models can influence medical decision making and the future of the technology in medicine. “The people who are developing [AI] models—they have no clue about the data provenance [in health care], says Celi. “We are surveying AI health courses online that have their syllabi available and none of them are really contributing enough time for asking the students: do you know how the data came about?”